• hlooho_banner_01

PT-141 ke eng?

Pontšo (tšebeliso e amohetsoeng): Ka 2019, FDA e ile ea e amohela bakeng sa kalafo ea lefu la takatso ea thobalano (HSDD) le fumanoeng ho basali ba premenopausal ha boemo bo baka khatello e matla mme e sa bakoe ke maemo a mang a bongaka/a kelello kapa litlamorao tsa lithethefatsi.

Mokhoa oa Ts'ebetso
PT-141 ke melanocortin receptor agonist (haholo-holo MC4 receptor) e fetolang takatso ea thobalano ka litsela tsa tsamaiso ea methapo e bohareng.

Ho fapana le PDE5 inhibitors (mohlala, sildenafil), e amang haholo methapo ea mali, PT-141 e sebetsa bohareng ho ama tšusumetso ea thobalano le ho tsosoa.

Pharmacology & Dosing
Tsamaiso: Ente e ka tlas'a letlalo, ha ho hlokahala (ha e batloa).
Tekanyetso e amohetsoeng: 1.75 mg sc

Pharmacokinetics:
Tmax ≈ ~ 60 metsotso
t½ ≈ lihora tse 2-3
Litlamorao li ka nka lihora tse 'maloa, litlalehong tse ling ho fihla ho lihora tse ~16.
Katleho ea Meriana (Liteko tsa Phase III - RECONNECT, libeke tsa 24, RCTs)

Lintlha tsa mantlha:
Female Sexual Function Index-Desire domain (FSFI-D)
Sekhahla sa Mathata a Thobalano ea Basali (FSDS-DAO)
Liphetho tsa bohlokoa (lithuto tse kopantsoeng 301 + 302):
Ntlafatso ea FSFI-D: +0.35 vs placebo (P<0.001)
Phokotso ea lintlha tsa FSDS-DAO: −0.33 vs placebo (P<0.001)
Liphello tse ling: Liphetho tse tšehetsang (lintlha tsa ts'ebetso ea thobalano, khotsofalo e tlalehiloeng ke mokuli) e ne e le e ntle, empa liketsahalo tsa thobalano tse khotsofatsang (SSEs) ha lia ka tsa bontša kamehla liphapang tse kholo.

Liketsahalo tse mpe (tse tlalehiloeng hangata litekong)
E tloaelehileng (≥10%):
Nausea (~ 30–40%; ho fihla ho ~ 40% e tlalehiloe litekong)
Ho hlatsoa (≥10%)
Hlooho e opang (≥10%)

Liphello tsa pelo:
Keketseho ea nakoana ea khatello ea mali le liphetoho tsa lebelo la pelo li ile tsa bonoa, hangata li rarolla ka mor'a lihora tse 'maloa.
Contraindicated kapa e sebelisoa ka hloko ho bakuli ba nang le khatello ea mali e sa laoleheng kapa lefu la pelo.
Sebete: Litlaleho tse sa tloaelehang tsa ho phahama ha enzyme ea sebete ea nakoana; Litlaleho tse sa tloaelehang haholo li fana ka maikutlo a hore ho ka ba le kotsi e mpe ea sebete, empa e sa tloaeleha.

Tšireletseho ea Nako e telele (Thuto ea Katoloso)
Phuputso ea libeke tse 52 ea katoloso ea li-label tse bulehileng e fumane ntlafatso e tsitsitseng ea takatso e se nang matšoao a macha a polokeho.
Boemo ba nako e telele ba ts'ireletso bo nkuoang bo mamelloa hantle, 'me mathata a mantlha a mamello e ntse e le litlamorao tsa nako e khuts'oane joalo ka ho nyekeloa ke pelo.

Lintlha tsa Tšebeliso ea Bohlokoa
Palo ea batho ba amohelehang e fokotsehile: Ke feela bakeng sa basali ba premenopausal ba nang le HSDD e fumanoeng, e akaretsang.
Ha e amoheloe ka bophara bakeng sa banna (ED kapa takatso e tlase ho banna e ntse e le lipatlisiso).
Tlhahlobo ea polokeho ke ea bohlokoa: khatello ea mali, lefu la pelo le nalane ea sebete li lokela ho hlahlojoa pele ho fanoa.

Kakaretso ea Lintlha tse Potlakileng
Tumello ea FDA: 2019 (Vyleesi).
Tekanyetso: 1.75 mg subcutaneous ente, ha ho hlokahala.
PK: Tmax ~ 60 min; t½ 2–3 h; litlamorao ho fihlela ho ~16 h.
Ho sebetsa hantle (Mokhahlelo oa Boraro, o kopane):
FSFI-D: +0.35 (P<.001)
FSDS-DAO: −0.33 (P<.001)

Liketsahalo tse mpe:
Nausea: ho fihlela ~ 40%
Flushing: ≥10%
Hlooho e opang: ≥10%
Keketseho ea BP ea nakoana e bonoa.

Tafole e Bapisang le Kerafo (Kakaretso)

Mofuta oa Thuto / Data Qetello / Lekanya Boleng / Tlhaloso
Mokhahlelo oa III (301+302 o kopane) FSFI-D (desre domain) + 0,35 vs placebo (P<0.001); FSDS-DAO -0.33
Liketsahalo Tse Mpe Ho nyekeloa ke pelo, ho hlatsa, hlooho Nausea ~ 30-40% (max ~ 40%); ho hlatsoa ≥10%; hlooho ≥10%

PT-141


Nako ea poso: Sep-30-2025